S
Suzanne Oparil
Researcher at University of Alabama at Birmingham
Publications - 941
Citations - 122414
Suzanne Oparil is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Blood pressure & Angiotensin II. The author has an hindex of 106, co-authored 885 publications receiving 113983 citations. Previous affiliations of Suzanne Oparil include Michigan State University & Oregon Health & Science University.
Papers
More filters
Journal ArticleDOI
The sympathetic nervous system in clinical and experimental hypertension.
TL;DR: In this article, the effects of renal denervation in one-kidney, one-clip and two-clip Goldblatt hypertensive rats suggest that renal afferent nerve activation contributes to the development of hypertension by causing increased renal sodium retention.
Journal ArticleDOI
Dietary compliance and cardiovascular risk reduction with a prepared meal plan compared with a self-selected diet.
Jill A. Metz,Penny M. Kris-Etherton,Cynthia D. Morris,V A Mustad,J. S. Stern,Suzanne Oparil,A. Chait,R. B. Haynes,L. M. Resnick,Sharon R. Clark,Daniel C. Hatton,Margaret McMahon,Scott Holcomb,Geoffrey W. Snyder,F. X. Pi-Sunyer,David A. McCarron +15 more
TL;DR: The prepared meal plan is a simple and effective strategy for meeting the many nutrient recommendations for CVD risk reduction and improving dietary compliance and CVD endpoints.
Journal ArticleDOI
Association Between Antihypertensive Medication Adherence and Visit-to-Visit Variability of Blood Pressure
Paul Muntner,Emily B. Levitan,Cara Joyce,Elizabeth W. Holt,Devin M. Mann,Suzanne Oparil,Marie Krousel-Wood +6 more
TL;DR: The data suggest that low antihypertensive medication adherence explains only a small proportion of VVV of systolic blood pressure (SBP), which is higher among participants with medium and low self‐report adherence.
Journal ArticleDOI
The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Ian M. Kronish,Amy I. Lynch,Suzanne Oparil,Jeff Whittle,Barry R. Davis,Lara M. Simpson,Marie Krousel-Wood,William C. Cushman,Tara I. Chang,Paul Muntner +9 more
TL;DR: In this paper, the authors assessed the association between antihypertensive medication adherence and visit-to-visit variability (VVV) of blood pressure in the AllHAT trial.
Journal ArticleDOI
Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial. Fenoldopam Study Group.
James A. Tumlin,Lala M. Dunbar,Suzanne Oparil,Vardaman M. Buckalew,C. Venkata S. Ram,Vandana Mathur,David Ellis,Dawn McGuire,Jere Douglas Fellmann,Robert R. Luther +9 more
TL;DR: Fenoldopam safely and effectively lowers blood pressure in a dose-dependent manner in patients with hypertensive emergencies, and there were no deaths or serious adverse events during follow-up, up to 48 hours.